Cinacalcet therapy in an infant with an R185Q calcium-sensing receptor mutation causing hyperparathyroidism: a case report and review of the literature.

Author: FormanThomas E, NallyLaura M, NiemiAnna-Kaisa, PrahaladPriya, ShiRun Zhang

Paper Details 
Original Abstract of the Article :
Background Neonatal severe hyperparathyroidism (NSHPT) is commonly treated with either parathyroidectomy or pharmacologic agents with varying efficacy and numerous side effects. Reports of using cinacalcet for NSHPT have increased, however, the effective dose for pediatric patients from the onset of...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://pubmed.ncbi.nlm.nih.gov/30730839

データ提供:米国国立医学図書館(NLM)

Cinacalcet: A Potential Solution in the Desert of Neonatal Hyperparathyroidism

Neonatal severe hyperparathyroidism (NSHPT) is a rare but serious condition that affects infants. This study reports a case of an infant with NSHPT who received treatment with cinacalcet, a medication that regulates calcium levels. The infant's serum calcium, phosphorus, and parathyroid hormone levels were effectively controlled with cinacalcet therapy. The study also reviews the literature on cinacalcet use in NSHPT, highlighting its potential as a treatment option for this condition.

Cinacalcet: A Hopeful Approach for Neonatal Hyperparathyroidism

This case report provides encouraging evidence for the use of cinacalcet in treating NSHPT. The medication effectively controlled the infant's hormone levels without any side effects. Further research is needed to confirm these findings and establish optimal dosing for infants.

Navigating the Desert of Childhood Disease

Childhood diseases can be challenging to manage, and NSHPT is no exception. This study highlights the potential of cinacalcet as a treatment option for this rare condition. Continued research is essential for developing safe and effective therapies for children with NSHPT.

Dr.Camel's Conclusion

The desert of childhood disease can be a difficult and uncertain landscape for parents and healthcare providers. This study offers a ray of hope for infants with NSHPT, demonstrating the potential of cinacalcet as a treatment option. Further research is needed to ensure its safety and efficacy, but this study provides a valuable starting point.

Date :
  1. Date Completed 2019-06-21
  2. Date Revised 2021-02-13
Further Info :

Pubmed ID

30730839

DOI: Digital Object Identifier

jpem-2018-0307

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.